You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):天士力生物獲臨牀試驗通知書
格隆匯 05-07 15:51

格隆匯5月7日丨天士力(600535.SH)公佈,公司控股子公司天士力生物醫藥股份有限公司(以下簡稱“天士力生物”)收到國家藥監局核准簽發的重組全人源抗PCSK9單克隆抗體注射液《臨牀試驗通知書》,並將於近期開展臨牀試驗。

重組全人源抗PCSK9單克隆抗體注射液是由天士力生物研究開發的治療用生物製品1類新藥,能特異性結合PCSK9 (Proprotein Convertase Subtilisin / KexinType 9,前蛋白轉化酶枯草溶菌素9),有效抑制PCSK9的功能、降低血漿中低密度脂蛋白膽固醇(LDL-C)水平,用於治療高膽固醇血癥,解決他汀類藥物副作用以及患者已接受最大劑量他汀類藥物治療但LDL-C仍未達標的問題,從而顯著降低動脈粥樣硬化性心血管疾病(ASCVD)的發病及死亡風險。截至公告日,天士力生物對重組全人源抗PCSK9單克隆抗體注射液研發累積投入人民幣4991.42萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account